Clovis Oncology (CLVS)’s CO-1686 Demonstrates Compelling Clinical Activity And Progression-Free Survival (PFS) In Updated Phase 1 Study Results In Patients With Non-Small Cell Lung Cancer (NSCLC)
3/27/2014 9:17:43 AM
GENEVA--(BUSINESS WIRE)--Clovis Oncology (NASDAQ:CLVS) announced today updated findings from the Phase 1 portion of its ongoing Phase 1/2 clinical study of CO-1686, the Company’s novel, oral, targeted covalent (irreversible) inhibitor of mutant forms of the epidermal growth factor receptor (EGFR) for the treatment of non-small cell lung cancer in patients with initial activating EGFR mutations as well as the dominant resistance mutation T790M. Interim results from the Phase 1 dose-escalation portion of this Phase 1/2 study are being presented today in an oral presentation by Dr. Heather Wakelee at the 4th European Lung Cancer Conference (ELCC) in Geneva.
Help employers find you! Check out all the jobs and post your resume.
comments powered by